NTRK1 and neoplasm: Similarly, tumour-specific mutations in the target tyrosine-kinase receptor may confer intrinsic resistance to TKI treatment, such as EGFR mutations in patients with lung adenocarcinoma [125] and PDGFR in gastrointestinal stromal tumours [126].